Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases
| Autor: | Laura La Corte, Elisabetta Gerratana, Donatella Sangari, Valeria Nucera, Fabiola Atzeni, Manuela Giallanza |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Cyclophosphamide MEDLINE Connective tissue Review Cochrane Library comorbidities behavioral disciplines and activities Pathogenesis 03 medical and health sciences 0302 clinical medicine Patient age Internal medicine medicine disease-modifying antirheumatic drugs interstitial lung diseases 030203 arthritis & rheumatology Pharmacology Lung business.industry lcsh:RM1-950 General Medicine respiratory system medicine.disease Connective tissue disease respiratory tract diseases body regions medicine.anatomical_structure lcsh:Therapeutics. Pharmacology 030228 respiratory system Molecular Medicine cyclophosphamide connective tissue diseases business medicine.drug |
| Zdroj: | Drugs in Context, Vol 10, Pp 1-9 (2021) Drugs in Context |
| ISSN: | 1740-4398 |
| Popis: | Interstitial lung diseases (ILDs) are some of the first and most serious complications of connective tissue diseases (CTDs). However, the pathogenesis of CTD-related ILDs (CTD-ILDs) is still unclear and their treatment often depends on functional and radiographic disease progression as well as on patient age and comorbidities. It can be difficult to manage CTD-ILDs due to their heterogeneous nature, the lack of robust therapeutic data, and the few well-defined outcome measures. This review focuses on cyclophosphamide due to its crucial role in the treatment of systemic sclerosis-related ILD, particularly in the case of patients with progressive ILD. This narrative review was performed using PubMed, Medline, and Cochrane Library databases to retrieve English language papers published between 2000 and April 2020 concerning the treatment of CTD-ILDs with cyclophosphamide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|